Once-Daily Atazanavir/Ritonavir Compared With Twice
Combination With Tenofovir and Emtricitabine, for Ma
HIV-1â€“Infected Patients: 96-Week Efficacy and Safety

Journal of Acquired Immune Deficiency Syndromes (1999)

53, 323-332

DOI: 10.1097/qai.0b013e3181c990bf

Citation Report

#	Article	IF	Citations
1	Antiretroviral Treatment 2010: Progress and Controversies. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S43-S48.	0.9	23
3	Long-term treatment of patients with HIV-1: the role of atazanavir. HIV/AIDS - Research and Palliative Care, 2010, 2, 157.	0.4	1
4	Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol, 2010, 2010, 1-13.	1.6	20
5	Risk factors for delayed HIV diagnosis at the hospital of tropical diseases in Ho Chi Minh City, Vietnam. International Journal of STD and AIDS, 2010, 21, 802-805.	0.5	8
6	Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 323-329.	0.9	81
7	Does lopinavir/ritonavir alter the primary gingival epithelium?. Expert Review of Anti-Infective Therapy, 2010, 8, 1345-1349.	2.0	1
8	Lopinavir/Ritonavir. Drugs, 2010, 70, 1885-1915.	4.9	103
9	Tratamiento de la infecciÃ³n por el VIH. FÃ¡rmacos antirretrovirales. Medicine, 2010, 10, 4048-4060.	0.0	0
10	Avances en el tratamiento de la infecciÃ³n por el virus de la inmunodeficiencia humana. Medicine, 2010, 10, 4716-4725.	0.0	1
11	Treatment of advanced HIV disease in antiretroviral-naÃ¯ve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1500-1504.	0.6	3
12	Drug combinations for HIV: whatâ€™s new?. Expert Review of Anti-Infective Therapy, 2011, 9, 1001-1011.	2.0	7
15	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research, 2011, 3, 197.	0.7	24
16	HIV protease inhibitors: present and future. Future Virology, 2011, 6, 571-580.	0.9	0
17	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2011, 11, 907-915.	4.6	175
18	Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. Virus Adaptation and Treatment, 2011, , 55.	1.5	3
19	Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy, 2011, 43, 89.	1.0	13
20	Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection. Virus Adaptation and Treatment, 0, , 25.	1.5	0
21	Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. Aids, 2011, 25, 185-195.	1.0	81

#	Article	IF	Citations
22	Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. Aids, 2011, 25, 1489-1496.	1.0	18
23	Optimizing Antiretroviral Product Selection: A Sample Approach to Improving Patient Outcomes, Saving Money, and Scaling-up Health Services in Developing Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S100-S103.	0.9	2
24	Lopinavir: the old champion. Future Virology, 2011, 6, 561-570.	0.9	1
25	Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. Annals of Internal Medicine, 2011, 154, 445.	2.0	287
26	Population pharmacokinetics of atazanavir/ritonavir in HIVâ€1â€infected children and adolescents. British Journal of Clinical Pharmacology, 2011, 72, 940-947.	1.1	12
27	Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. Journal of Infection and Chemotherapy, 2011, 17, 602-608.	0.8	8
28	Antiretroviral therapy 2010 update: Current practices and controversies. Archives of Pharmacal Research, 2011, 34, 1045-53.	2.7	5
29	Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virology, 2011, 6, 157-177.	0.9	41
30	Health Needs of HIV-Infected Women in the United States: Insights from The Women Living Positive Survey. AIDS Patient Care and STDs, 2011, 25, 279-285.	1.1	65
31	Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naÃ¯ve human immunodeficiency virus-infected patients in the United States. Journal of Medical Economics, 2011, 14, 167-178.	1.0	11
32	Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naÃ¯ve human immunodeficiency virus-1 patients in Sweden. Scandinavian Journal of Infectious Diseases, 2011, 43, 304-312.	1.5	6
33	Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults. AIDS Research and Human Retroviruses, 2011, 27, 1061-1065.	0.5	12
34	Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. Journal of Antimicrobial Chemotherapy, 2011, 66, 363-370.	1.3	61
35	Antiretroviral therapy in treatment-naÃ¯ve patients with HIV infection. Current Opinion in HIV and AIDS, 2011, 6, S3-S11.	1.5	23
36	Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. Journal of Antimicrobial Chemotherapy, 2011, 66, 1869-1877.	1.3	7
37	Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India. Journal of the International Association of Providers of AIDS Care, 2011, 10, 111-118.	1.2	1
38	Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-NaÃ¯ve HIV-Infected Patients. HIV Clinical Trials, 2011, 12, 151-160.	2.0	3
39	Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription. International Journal of STD and AIDS, 2012, 23, 865-869.	0.5	4

#	Article	IF	Citations
40	Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks. AIDS Research and Human Retroviruses, 2012, 28, 1184-1195.	0.5	74
41	Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2012, 28, 165-170.	0.5	2
42	In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	1.4	118
43	Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era. Clinical Infectious Diseases, 2012, 55, 860-867.	2.9	64
44	Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy. Journal of the International Association of Providers of AIDS Care, 2012, 11, 252-259.	1.2	6
45	Symptomatic Hyperbilirubinemia Secondary to Dapsone-Induced Hemolysis and Atazanavir Therapy. Antimicrobial Agents and Chemotherapy, 2012, 56, 1081-1083.	1.4	8
46	Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Journal of Antimicrobial Chemotherapy, 2012, 67, 465-468.	1.3	18
47	Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy, 2012, 67, 312-321.	1.3	22
48	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1462-1469.	1.3	4
49	High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 55, 1262-1269.	2.9	80
50	Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Journal of Antimicrobial Chemotherapy, 2012, 67, 995-1000.	1.3	26
51	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	4.3	31
52	Type I aortic dissection in a patient with human immunodeficiency virus infection. BioScience Trends, 2012, 6, 143-6.	1.1	1
53	Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1305-1314.	1.5	9
54	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 33-42.	0.9	151
55	Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies. Clinical Investigation, 2012, 2, 1133-1144.	0.0	1
56	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. Journal of Chemotherapy, 2012, 24, 38-47.	0.7	2
57	Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study. HIV Clinical Trials, 2012, 13, 111-117.	2.0	0

#	Article	IF	Citations
58	Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1â€“Infected Patients With or Without Hepatitis B or C Coinfection. HIV Clinical Trials, 2012, 13, 171-177.	2.0	6
59	Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003â€“2010. Antiviral Therapy, 2012, 17, 993-999.	0.6	14
60	Novel clinical trial designs for the development of new antiretroviral agents. Aids, 2012, 26, 899-907.	1.0	13
61	Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART Through Clinical Trials Compared With Routine Care in Mexico. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 155-160.	0.9	11
62	Atazanavir Pharmacokinetics, Efficacy and Safety in Pregnancy: A Systematic Review. Antiviral Therapy, 2013, 18, 361-375.	0.6	16
63	Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 39-46.	0.9	155
64	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, The, 2012, 379, 2429-2438.	6.3	317
65	Treatment of HIV infection with once-daily regimens. Expert Opinion on Pharmacotherapy, 2012, 13, 2301-2317.	0.9	27
66	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis, 2012, 225, 200-207.	0.4	30
67	Clinical Significance of Hyperbilirubinemia Among HIV-1â€“Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. AIDS Patient Care and STDs, 2012, 26, 259-264.	1.1	26
68	Monitoring the Risk of Birth Defects Associated with Atazanavir Exposure in Pregnancy. AIDS Patient Care and STDs, 2012, 26, 307-311.	1.1	5
69	Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opinion on Pharmacotherapy, 2012, 13, 1363-1375.	0.9	13
70	Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naÃ¯ve and -experienced United Kingdom patients in 2011. Journal of Medical Economics, 2012, 15, 796-806.	1.0	7
72	Renal Toxicity Associated With Antiretroviral Therapy. HIV Clinical Trials, 2012, 13, 189-211.	2.0	44
73	Hyperbilirubinemia during therapy with atazanavir boosted with ritonavir in HIV-infected patients in Lodz region. HIV and AIDS Review, 2012, 11, 54-56.	0.1	1
74	Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study. HIV and AIDS Review, 2012, 11, 77-83.	0.1	2
75	Overview of antiretroviral therapy. , 2012, , 133-153.		0
76	Long-Term Use of Atazanavir in the Treament of HIV-Infected patients. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S5764.	0.4	2

#	Article	IF	Citations
77	New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. ClinicoEconomics and Outcomes Research, 2012, 4, 193.	0.7	20
78	Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 489-493.	0.9	33
79	Lipid Profile Changes after Switch to Atazanavir from other Protease Inhibitor-based Combined Antiretroviral Treatment in HIV-infected Korean. Infection and Chemotherapy, 2012, 44, 377.	1.0	0
82	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	3.3	247
83	Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. Future Virology, 2013, 8, 1021-1034.	0.9	8
84	Clinical and Pharmacogenetic Factors Affecting Neonatal Bilirubinemia Following Atazanavir Treatment of Mothers During Pregnancy. AIDS Research and Human Retroviruses, 2013, 29, 1287-1292.	0.5	5
85	Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2013, 29, 564-573.	0.5	9
86	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.3	45
87	Number of daily pills, dosing schedule, selfâ€reported adherence and health status in 2010: a large crossâ€sectional study of <scp>HIV</scp>â€infected patients on antiretroviral therapy. HIV Medicine, 2013, 14, 153-160.	1.0	23
88	Komentarz do rekomendacji PTN AIDS 2013 â€“ rozpoczynanie i monitorowanie leczenia antyretrowirusowego. HIV and AIDS Review, 2013, 12, 109-112.	0.1	0
89	Antiretroviral drug-related toxicities â€“ clinical spectrum, prevention, and management. Expert Opinion on Drug Safety, 2013, 12, 697-707.	1.0	23
90	Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naÃ¯ve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. Scandinavian Journal of Infectious Diseases, 2013, 45, 543-551.	1.5	14
91	HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy. Drugs, 2013, 73, 1431-1450.	4.9	47
92	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Journal of Antimicrobial Chemotherapy, 2013, 68, 200-205.	1.3	14
93	Optimizing HIV treatment. Current Opinion in HIV and AIDS, 2013, 8, 34-40.	1.5	11
94	High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 1850-1856.	1.3	36
95	Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2013, 57, 3640-3644.	1.4	9
96	96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antiviral Therapy, 2013, 18, 967-977.	0.6	39

#	Article	IF	Citations
97	Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100â€Š000â€Šcopies/ml or less. Aids, 2013, 27, 889-897.	1.0	26
98	Time-Dependent Interaction of Ritonavir in Chronic Use: The Power Balance Between Inhibition and Induction of P-Glycoprotein and Cytochrome P450 3A. Journal of Pharmaceutical Sciences, 2013, 102, 2044-2055.	1.6	11
99	Maternal Atazanavir Usage in HIV-Infected Pregnant Women and the Risk of Maternal and Neonatal Hyperbilirubinemia. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e158-e159.	0.9	2
100	Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV/AIDS - Research and Palliative Care, 2013, 5, 153.	0.4	16
101	An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV/AIDS - Research and Palliative Care, 2013, 5, 231.	0.4	5
102	Provider Compliance With Guidelines for Management of Cardiovascular Risk in HIV-Infected Patients. Preventing Chronic Disease, 2013, 10, E10.	1.7	42
103	The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection and Chemotherapy, 2013, 45, 455.	1.0	16
104	Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)- Containing Regimens in Treatment-Experienced Patients with HIV. Current HIV Research, 2013, 11, 333-341.	0.2	8
105	Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World. PLoS ONE, 2013, 8, e57777.	1.1	13
106	Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients. PLoS ONE, 2013, 8, e77268.	1.1	17
107	Lopinavir/r no longer recommended as a firstâ€line regimen: a comparative effectiveness analysis. Journal of the International AIDS Society, 2014, 17, 19070.	1.2	6
108	Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 403-12.	0.4	15
109	HIV medication-based urolithiasis. CKJ: Clinical Kidney Journal, 2014, 7, 121-126.	1.4	32
112	Increases in Duration of First Highly Active Antiretroviral Therapy Over Time (1996â€“2009) and Associated Factors in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 57-64.	0.9	23
113	Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-NaÃ¯ve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies. HIV Clinical Trials, 2014, 15, 231-245.	2.0	25
114	Antiretrovirals and the kidney in current clinical practice. Aids, 2014, 28, 621-632.	1.0	93
115	Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 1385-1389.	1.3	13
116	7.0â€‚Managing virological failure. HIV Medicine, 2014, 15, 48-57.	1.0	2

#	Article	IF	Citations
117	Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. HIV Medicine, 2014, 15, 224-232.	1.0	6
118	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. Journal of Antimicrobial Chemotherapy, 2014, 70, 1130-8.	1.3	18
119	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenetics and Genomics, 2014, 24, 459-463.	0.7	21
120	HIV infection and cardiovascular disease. European Heart Journal, 2014, 35, 1373-1381.	1.0	198
121	Comparison of Body Composition Changes Between Atazanavir/Ritonavir and Lopinavir/Ritonavir Each in Combination with Tenofovir/Emtricitabine in Antiretroviral-NaÃ¯ve Patients with HIV-1 Infection. Clinical Drug Investigation, 2014, 34, 287-296.	1.1	11
122	What to do Next? Second-line Antiretroviral Therapy. Current Treatment Options in Infectious Diseases, 2014, 6, 159-170.	0.8	1
123	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1â€“Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. HIV Clinical Trials, 2014, 15, 151-160.	2.0	10
124	Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 439-456.	1.9	9
126	Beginning Antiretroviral Therapy for Patients with HIV. Infectious Disease Clinics of North America, 2014, 28, 421-438.	1.9	5
127	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. Journal of Antimicrobial Chemotherapy, 2014, 69, 573-581.	1.3	56
128	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1377-1384.	1.3	13
129	AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000â€“2008: hospital-based cohort studies. BMC Infectious Diseases, 2014, 14, 278.	1.3	27
130	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. Journal of Global Antimicrobial Resistance, 2014, 2, 103-106.	0.9	1
131	Tratamiento de la infecciÃ³n por el VIH. Medicine, 2014, 11, 2912-2919.	0.0	0
132	A systematic review of the use of atazanavir in women infected with HIV type-1. Antiviral Therapy, 2014, 19, 293-307.	0.6	4
133	Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: The CASTLE biomarker substudy. Antiviral Therapy, 2014, 19, 693-699.	0.6	1
134	Incidence and Determinants of Severe Morbidity among HIV-Infected Patients from Rio De Janeiro, Brazil, 2000â€“2010. Antiviral Therapy, 2014, 19, 387-397.	0.6	14
135	Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. Lancet HIV,the, 2015, 2, e474-e482.	2.1	60

#	Article	IF	Citations
136	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1â€“Infected Patients Starting Efavirenz, Lopinavirâ€“Ritonavir, or Atazanavirâ€“Ritonavir Plus Tenofovir/Emtricitabine. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 206-215.	0.9	14
137	Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 493-498.	0.9	82
138	Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infection and Chemotherapy, 2015, 47, 231.	1.0	30
139	Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens. PLoS ONE, 2015, 10, e0124666.	1.1	6
140	The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection and Chemotherapy, 2015, 47, 205.	1.0	10
141	PRINCEâ€1: safety and efficacy of atazanavir powder and ritonavir liquid in HIVâ€1â€infected antiretroviralâ€naÃ¯ve and â€experienced infants and children aged â‰¥3 months to <6 years. Journal of the International AIDS Society, 2015, 18, 19467.	1.2	9
142	Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. AIDS Research and Treatment, 2015, 2015, 1-7.	0.3	6
143	Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS. Critical Reviews in Therapeutic Drug Carrier Systems, 2015, 32, 503-533.	1.2	6
144	Seven years of chronic hepatitis C virus infection in an HIV-infected man without detectable antibodies. Aids, 2015, 29, 389-390.	1.0	2
145	Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clinical Trials, 2015, 16, 89-99.	2.0	7
146	Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy. HIV Clinical Trials, 2015, 16, 163-169.	2.0	8
147	Boosted Lopinavirâ€ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	2.9	6
148	Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review. Infectious Diseases and Therapy, 2015, 4, 15-50.	1.8	30
149	Atazanavir nephrotoxicity. CKJ: Clinical Kidney Journal, 2015, 8, 137-142.	1.4	39
150	When can HIV clinical trials detect treatment effects on drug resistance?. International Journal of STD and AIDS, 2015, 26, 268-278.	0.5	1
151	Dual treatment with atazanavirâ€“ritonavir plus lamivudine versus triple treatment with atazanavirâ€“ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 775-784.	4.6	122
153	Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 3816-3822.	1.4	18
154	Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration. Aids, 2015, 29, 390-392.	1.0	5

#	Article	IF	Citations
155	Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir. Aids, 2015, 29, 392-394.	1.0	1
156	Changes in Metabolic Syndrome Status After Initiation of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 73-80.	0.9	25
157	Efficacy and safety of lopinavir/ritonavir-based antiretroviral therapy in HIV-1-infected subjects with advanced disease: a systematic review and meta-analysis. Future Virology, 2015, 10, 949-959.	0.9	0
158	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. Journal of Antimicrobial Chemotherapy, 2015, 70, 3087-3095.	1.3	13
159	Antiretroviral Agent. , 0, , 169-214.		1
160	Survival benefits of antiretroviral therapy in Brazil: a modelâ€based analysis. Journal of the International AIDS Society, 2016, 19, 20623.	1.2	19
161	Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia. PLoS ONE, 2016, 11, e0160306.	1.1	17
162	Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025. PLoS ONE, 2016, 11, e0164619.	1.1	41
163	Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice. Antiviral Therapy, 2016, 21, 715-724.	0.6	0
164	Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV,the, 2016, 3, e343-e350.	2.1	26
165	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). Journal of Antimicrobial Chemotherapy, 2016, 71, 2252-2261.	1.3	7
166	Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. Antimicrobial Agents and Chemotherapy, 2016, 60, 3956-3969.	1.4	58
167	Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1321-1326.	0.6	5
168	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV,the, 2016, 3, e510-e520.	2.1	151
169	British HIV Association guidelines for the treatment of <scp>HIV</scp>â€1â€positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78
170	Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIVâ€1 infected patients. British Journal of Clinical Pharmacology, 2016, 82, 1528-1538.	1.1	5
171	Hyperbilirubinaemia in HIVâ€“HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterology, 2016, 3, e000072.	1.1	0
172	Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials, 2016, 17, 72-77.	2.0	15

#	Article	IF	Citations
173	HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. Progress in Cardiovascular Diseases, 2016, 58, 565-576.	1.6	42
174	Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-NaÃ¯ve Patients with HIV-1 Infection: the REMAIN Study. HIV Clinical Trials, 2016, 17, 17-28.	2.0	4
175	Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Review of Anti-Infective Therapy, 2017, 15, 569-576.	2.0	9
176	Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis. Archives of Virology, 2017, 162, 2181-2190.	0.9	9
177	Odds of Viral Suppression by Singleâ€Tablet Regimens, Multipleâ€Tablet Regimens, and Adherence Level in <scp>HIV</scp>/<scp>AIDS</scp> Patients Receiving Antiretroviral Therapy. Pharmacotherapy, 2017, 37, 204-213.	1.2	35
178	Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil. Journal of the International AIDS Society, 2017, 20, 21405.	1.2	6
179	Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV,the, 2017, 4, e433-e441.	2.1	60
180	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naÃ¯ve patients. BMC Infectious Diseases, 2017, 17, 266.	1.3	7
181	Deep sequencing for HIV-1 clinical management. Virus Research, 2017, 239, 69-81.	1.1	44
182	Antiviral Therapy. , 2017, , 918-926.e1.		1
183	Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Current HIV Research, 2017, 15, 216-224.	0.2	5
184	IN SILICO STUDIES ON FUNCTIONALIZED AZAGLYCINE DERIVATIVES CONTAINING 2, 4-THIAZOLIDINEDIONE SCAFFOLD ON MULTIPLE TARGETS. International Journal of Pharmacy and Pharmaceutical Sciences, 2017, 9, 209.	0.3	6
185	Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	1.3	2
186	Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1025-1030.	1.3	3
187	Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age. Pediatric Infectious Disease Journal, 2018, 37, e149-e156.	1.1	3
188	Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired <scp>HIV</scp> on older protease inhibitors: results from the Pediatric <scp>HIV</scp>/<scp>AIDS</scp> Cohort Study. HIV Medicine, 2018, 19, 175-183.	1.0	6
189	Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. Antiviral Therapy, 2018, 23, 699-703.	0.6	2
190	Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Design, Development and Therapy, 2018, Volume 12, 3635-3643.	2.0	12

#	Article	IF	Citations
191	New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations. Aids, 2018, 32, 2593-2603.	1.0	21
192	Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Bioscience Reports, 2018, 38, .	1.1	6
193	Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Frontiers in Public Health, 2018, 6, 63.	1.3	6
194	Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. Journal of Antimicrobial Chemotherapy, 2018, 73, 2162-2170.	1.3	6
195	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Research and Therapy, 2019, 16, 34.	0.7	16
196	Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in SÃ£o Paulo State, Brazil. PLoS ONE, 2019, 14, e0223210.	1.1	2
197	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	1.3	11
198	An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. BMC Infectious Diseases, 2019, 19, 280.	1.3	4
199	The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection and Chemotherapy, 2019, 51, 77.	1.0	12
200	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 1679-1692.	1.3	8
201	Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir. Pharmacogenomics, 2019, 20, 105-111.	0.6	7
202	The clinical pharmacology of integrase inhibitors. Expert Review of Clinical Pharmacology, 2019, 12, 31-44.	1.3	6
203	Drugâ€“drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. CNS Spectrums, 2019, 24, 287-312.	0.7	28
204	Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients. Acta Clinica Belgica, 2019, 74, 143-150.	0.5	0
205	Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies . HIV/AIDS - Research and Palliative Care, 2020, Volume 12, 507-524.	0.4	8
206	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load â‰¤50 copies/mL: does estimated glomerular filtration rate matter?. International Journal of Antimicrobial Agents, 2020, 56, 106154.	1.1	1
207	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. Journal of Antimicrobial Chemotherapy, 2020, 75, 3334-3343.	1.3	5
208	Role of the Pharmacist in Improving Accessibility of Antiretrovirals to Support the United States President's Emergency Plan for AIDS Relief: Impact on the Patient, Program, and Market. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 980.	0.5	1

#	Article	IF	Citations
209	High rate of major drugâ€“drug interactions of lopinavirâ€“ritonavir for COVID-19 treatment. Scientific Reports, 2020, 10, 20958.	1.6	15
210	Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis. African Health Sciences, 2020, 20, 91-101.	0.3	6
211	Predictors of Viremia in Postpartum Women on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 72-80.	0.9	5
212	Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy, 2021, 53, 592.	1.0	9
213	Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naÃ¯ve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infectious Diseases, 2021, 21, 222.	1.3	26
214	Stop â€˜controllingâ€™ for sex and gender in global health research. BMJ Global Health, 2021, 6, e005714.	2.0	42
215	Cardiovascular risks associated with protease inhibitors for the treatment of HIV. Expert Opinion on Drug Safety, 2021, 20, 1351-1366.	1.0	5
216	Dyslipidemia in HIV-Infected Patients. Contemporary Endocrinology, 2015, , 155-176.	0.3	2
218	Deficient Reporting and Interpretation of Non-Inferiority Randomized Clinical Trials in HIV Patients: A Systematic Review. PLoS ONE, 2013, 8, e63272.	1.1	25
219	Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?. PLoS ONE, 2013, 8, e69845.	1.1	10
220	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	1.1	5
221	Adult antiretroviral therapy guidelines 2017. Southern African Journal of HIV Medicine, 2017, 18, 776.	0.3	155
222	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. Southern African Journal of HIV Medicine, 2020, 21, 1115.	0.3	29
223	Endothelial Dysfunction in HIV. , 0, , .		1
224	Adverse Drug Reaction Reports in an Antiretroviral Treatment Centre in Jos, North Central Nigeria. British Journal of Pharmaceutical Research, 2014, 4, 714-721.	0.4	2
225	Effect of Ritonavir-boosting on Atazanavir Discontinuation due to Jaundice in HIV-infected Koreans. Infection and Chemotherapy, 2012, 44, 175.	1.0	1
227	Longâ€•term effectiveness of initiating nonâ€•nucleoside reverse transcriptase inhibitorâ€•versus ritonavirâ€boosted protease inhibitorâ€based antiretroviral therapy: implications for firstâ€•line therapy choice in resourceâ€•limited settings. Journal of the International AIDS Society, 2016, 19, 20978.	1.2	0
228	Inhibiteurs de protÃ©ase. , 2018, , 143-151.		0

#	Article	IF	Citations
229	KIDNEY LESIONS IN HIV PATIENTS. IATROGENIC LESIONS AND THEIR DIAGNOSTICS AND TREATMENT. Part 2. HIV Infection and Immunosuppressive Disorders, 2018, 10, 28-42.	0.1	2
231	HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2021, 12, 635089.	1.6	12
232	Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview. P and T, 2011, 36, 332-45.	1.0	22
233	Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy. Drug Design, Development and Therapy, 2022, Volume 16, 297-304.	2.0	12
234	Outcomes in HIV patients on two different protease inhibitors on second-line antiretroviral therapy: An observational study. Journal of Marine Medical Society, 2022, .	0.0	0
235	Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Journal of the International Association of Providers of AIDS Care, 2022, 21, 23259822210882.	0.6	4
236	Part I: Interactive case: Hyperlipidemia management for special populations. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 1011-1015.	0.5	0